One year after starting this treatment, offered by the French company Ose Immunotherapeutics, more than 44% of patients were still alive, according to the results of a clinical trial.
Published
Reading time : 1 min.
:quality(50)/2023/09/11/069-bsip-016220-588-64ff749188cea955398515.jpg)
These results allow “to consider new hope for these patients”, according to Nicolas Poirier. The CEO of Ose Immunotherapeutics revealed, Monday September 11, the positive results of its therapeutic vaccine Tedopi, offered to people with advanced lung cancer. The results of a phase 3 clinical trial, therefore before marketing, have been published in the journal Annals of Oncology.
The study demonstrates a reduced risk of death compared to chemotherapy.“One year after the start of treatment, 44.1% of these patients were still alive in the group receiving the vaccine compared to only 27.5% in the chemotherapy group”, we can read in the article. For Professor Benjamin Besse, director of clinical research at the Gustave-Roussy Institute, these results also show that “the vaccine (…) makes it possible to maintain a better quality of life for patients” And “fewer side effects”, than chemotherapy.
Two hundred and nineteen patients participated in the study, in nine European countries as well as the United States. These results make it possible to identify which patients could benefit from it, if Tedopi were marketed: these are “patients who initially responded to immunotherapy before relapsing”, specified Benjamin Besse. Therapeutic cancer vaccines aim to educate the immune system, with the aim of specifically recognizing and destroying cancer cells.